Filtered By:
Source: Circulation
Condition: Heart Attack
Drug: Dapagliflozin
Nutrition: Weight Loss
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes: Cardiovascular and Kidney Effects, Potential Mechanisms and Clinical Applications.
Abstract
Sodium glucose co-transporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin and canagliflozin, are now widely approved anti-hyperglycemic therapies. Due to their unique glycosuric mechanism, SGLT2 inhibitors also reduce weight. Perhaps more importantly are osmotic diuretic and natriuretic effects contributing to plasma volume contraction, and decreases in systolic and diastolic blood pressures (BP) by 4-6/1-2 mmHg, respectively, which may underlie cardiovascular and kidney benefits. SGLT2 inhibition is also associated with an acute, dose-dependent reduction in eGFR by ~5 ml/min/1.73m(2) and...
Source: Circulation - July 27, 2016 Category: Cardiology Authors: Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ Tags: Circulation Source Type: research
